Adagene
ADAGAdagene is a China-based biotech focused on developing novel antibody therapeutics for cancer using its proprietary computational and AI-driven discovery platform. Its core technology, the Dynamic Precision Library (DPL), enables the generation of highly diverse and functional antibody candidates. The company has advanced multiple candidates into clinical trials and has established strategic partnerships with major pharmaceutical players. Its strategy centers on creating safer and more effective immuno-oncology treatments with improved therapeutic windows.
ADAG · Stock Price
Historical price data
AI Company Overview
Adagene is a China-based biotech focused on developing novel antibody therapeutics for cancer using its proprietary computational and AI-driven discovery platform. Its core technology, the Dynamic Precision Library (DPL), enables the generation of highly diverse and functional antibody candidates. The company has advanced multiple candidates into clinical trials and has established strategic partnerships with major pharmaceutical players. Its strategy centers on creating safer and more effective immuno-oncology treatments with improved therapeutic windows.
Technology Platform
Proprietary Dynamic Precision Library (DPL) platform integrating computational design, AI, and antibody engineering to generate novel antibodies, including conditionally activated SAFEbody and enhanced POWERbody therapeutics.
Pipeline
9| Drug | Indication | Stage | Watch |
|---|---|---|---|
| ADG126 + Pembrolizumab | Locally Advanced Colorectal Cancer | Phase 2 | |
| ADG106 injection + PD-1 antibody injection | Solid Tumor | Phase 1/2 | |
| ADG106 + Doxorubicin + Cyclophosphamide + Paclitaxel | HER2-negative Breast Cancer | Phase 1/2 | |
| ADG126 Mono + ADG126-anti PD1 + ADG126-ADG106 | Advanced/Metastatic Solid Tumors | Phase 1/2 | |
| ADG116 | Solid Tumor | Phase 1 |
Opportunities
Risk Factors
Competitive Landscape
Adagene competes in the next-generation immuno-oncology space against companies like CytomX (Probody platform), Agenus (botensilimab), and numerous developers of CD137 agonists and bispecific antibodies. Its main differentiation is the integrated AI-driven discovery (DPL) combined with proprietary masking (SAFEbody) and enhancing (POWERbody) technologies, aiming to produce optimally designed therapeutics from the outset.